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ABSTRACT
By combining various cancer cell line (CCL) drug screening panels, the size of the data has grown
significantly to begin understanding how advances in deep learning can advance drug response pre-
dictions. In this paper we train >35,000 neural network models, sweeping over common featurization
techniques. We found the RNA-seq to be highly redundant and informative even with subsets larger
than 128 features. We found the inclusion of single nucleotide polymorphisms (SNPs) coded as
count matrices improved model performance significantly, and no substantial difference in model
performance with respect to molecular featurization between the common open source MOrdred
descriptors and Dragon7 descriptors. Alongside this analysis, we outline data integration between
CCL screening datasets and present evidence that new metrics and imbalanced data techniques, as
well as advances in data standardization, need to be developed.
1 Introduction
The crux of precision oncology and virtual drug screening lies in the relationship between molecular structure and
cancer genetics [1, 2]. It is well studied that cancer genetics may play a role in drug efficacy even across similar cancer
types [3]. In order to understand this relationship, drug screening assays such as the NCI-60 Human Tumor Cell Line
Screen were created to drive the precision oncology search for the link. Recently, deep learning has been applied to
the problem as a means of modeling the interaction between cell genetics and drug properties [4, 5, 6, 7]. We aim to
explore the impact of featurization on a small subset of the possible feature space utilizing multiple combined dose
response data.
Classical machine learning models such as Random Forest have been used in typing cancer genetics and even in single
agent drug response models [8, 9, 10]; however, most of these studies create single models based either predicting
the response of a single cell given various drugs or predicting the activity of a drug over different cell lines. Few
classical models have shown success across a wide range of CCLs and a diverse set of drugs in a single multitask model.
Deep learning provides a more natural interface as higher dimensional datasets can be applied and reduced to a lower
dimensional representation, where the choice of representation of the data is still important [11].
Prior featurization techniques were studied by Jang et. al, where they systematically analyzed CCL drug sensitivity
modeling as a classical machine learning task, by exploring the multitude of feature modalities, algorithms, prediction
targets, and more [12]. Given that they had a small set of drugs available between the studies (138 compound), the
models Jang et. al studied did not featurize the drugs in a continuous embedding; rather they were one-hot encoded
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whether present or not. Overall, in explaining the predictive variance between the over 110,000 models tested, they
ranked the factors for variance among models, finding genetic features and the particular compound being predicted to
be very explanatory, while the algorithm being considerably less important. Their results were further in line with other
work on more general learning problems involving genetic features [13].
While many drug feature representations such as SMILES based encoders [4] or pharmacophore models [14] are
commonly used in deep learning models, we chose to compare only two variants of molecular descriptors: Mordred and
Dragon7, which are some of the more common classical feature representations [15, 16]. Deep learning models may be
moving toward more natural representations such as graphical representations; however, even the integrated dataset
does not offer the sort of drug diversity seen in the papers effectively using these newer representations [17].
Across the recent works, the decision to use RNA-seq in conjunction with images, SMILES, or fingerprints was a choice
dictated by the desired model architecture, explainability of the model, or resources available; however, these choices do
not span the entire space of representations available for cells nor drugs. Cortés-Ciriano and Bender found introducing
convolutional neural networks (CNNs) for the drug image alongside Morgan fingerprints improved performance of
cell line sensitivity predictions with a small effect size [5]. Manica et al. compared fingerprints to the use of SMILES
strings, showing an RMSE improvement from 0.122± 0.010 their deep baseline to 0.104± 0.005 in IC50 predictions
with the benefit of an explainability mechanism for improved mechanism of action (MOA) and perturbation study
[4]. Xia et al. found the use of proteome, expression, and molecular fingerprints to perform the best when studying
combinations of drug pairs; however, proteome data is not available at scale of this study [6]. Chang et al. utilized a
virtual docking technique in conjunction with CNNs to achieve r2 > 0.84 on 244 drugs from GDSC [7]. Rampášek et
al. used gene perturbation data in an autoencoder [18]. The goal of these models is to provide insight into which drugs
and cells should be tested in downstream drug development analysis with, for example, PDX models or organoids.
In this work, we outline multiple methods for preparation of pan-cancer data, training strategies, and analysis strategies
of these models. As opposed to a hyperparameter optimization experiment which would provide a single predictive
model, we aim to understand a small section of the overall feature space: primarily which genetic features are most
effective and whether or not MOrdred open-source descriptors compare to Dragon7 descriptors. While performing
hyperparameter optimization on each individual model is ideal, this is not tractable given the sheer number of simple
discrete permutations available. In an attempt to approximate the optimization task, we also sweep over various model
architectures, training strategies, and other learning hyperparameter optimization runs on models. Our results aim to
provide guidelines for creating deep learning models for CCL models across studies, with the hope that more researchers
continue to explore the space.
In order to facilitate downstream analysis, we are releasing all the code to generate the data from public sources and
data collected from the model runs. Details on data preparation and deep learning methods utilized are in the materials
and method section1.
2 Results
We report on the results of models based on predictions on their assigned validation set and metrics. In terms of
understanding the parameter space, we ran a series of classical machine learning predictors trained on the hyperparameter
configuration to predict our four key metrics: RMSE, r2, balanced accuracy, and MCC (Figure 1). The results indicate
standard deep learning hyperparameters to play the most important role in variance, rather than specific feature
information, as optimizer, model architecture, training strategy, and dropout all are more predictive using SNPs or the
featurization of drugs or cells.
2.1 Features Representation
The inclusion of SNPs improves performance on cell validation split models in RMSE, r2, MCC, and balanced accuracy
(Table 1). There was no calculated metric in our test suite which reported a worse score when SNPs were included (at
100% and 99% percentiles). For the on cell validation method, the independent t-test shows significant improvement
RMSE and r2 scores with the inclusion of SNP features (p < 10−5), and less significant improvement for balanced
accuracy and MCC (p < 0.17 and p < 0.02 respectively). For drug validation models, the RMSE and r2 are again
significantly different with the inclusion of SNP features (p < 0.003 and p < 0.0005) and not as significant for balanced
accuracy and MCC (p < 0.01 and p < 0.3).
Scaling methods did not seem to have a large effect on the variance between models besides source scaling seemed to
improve measures slightly (Table 2. According to an ANOVA the null hypothesis of similarity among scaling methods is
1Please see https://github.com/DOE-NCI-Pilot1/CCLFeatureComparison
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Figure 1: (Left) The AUC distribution of pan-cancer data frame. With this scheme, the training distribution has 3.86%
responders. While our cutoff of 0.5 is arbitrary, learning to distinguish this slice along with a regression-based training
strategy will prevent standard regression metrics from appearing much better than they are on the skewed portion of the
dataset. (Right)Relative feature importance for hyperparameters used in model training for predicting validation metric
using decision trees. The r2 for those models were > 0.9 on cell validation metrics, and > 0.6 for drug validation
metrics. Optimizer, model type, and dropout were among the top three features, though the training strategy very
important when predicting balanced accuracy.
not rejected for either validation method (p < 0.14). Cell frame splits did not have any noticeable differences amongst
them (Table 3). According to an ANOVA test for fit, there is no significant difference among cell validation methods
(p < 0.31) and the drug validation method shows a possible difference but nothing significant (p < 0.06).
The different chemical informatics package used to features the molecules did not have a significant effect on the
validation scores (Table 4). For on cell validation models, no reported metric rejects the hypothesis that all featurization
are the same for p < 0.09; however, for on drug validation RMSE and r2 scores are effected by featurization to an
extent (p < 0.0001). We applied post hoc analysis to these two metrics using John Turkey’s HSD analysis which shows
Dragon7 and MOrdred slightly different on r2 and RMSE (p < 0.05). The use of both MOrdred and Dragon7 however
is significantly different from just using Dragon7 on both metrics (p < 0.01).
3 Discussion
We first comment on the overall model performance of a few models created in this study. Second, we evaluate prior
claims that feature representation should matter as the primary explanation of variance between models. We finally
evaluate the three significant findings to consider in future research when building DNN models on CCL sensitivity
predictions such as the drug featurization, training strategies, and the inclusion of SNPs.
In general, we found the best models to perform quite well on the validation data in both regression and classification
contexts. There are models with validation scores on unseen cells of r2 > 0.7 and balanced accuracy > 90%, and
there are models with validation on unseen drugs with r2 > 0.55 and balanced accuracy > 84%. The cross-study
performance of the two best cell validation models (Table 6) are on par with several other studies, though not more
predictive on a single drug basis. The models in table 6 are also top ranked if a simple average is taken across the
cross-study measures as well. Models validated with unseen cells outperform models trained with unseen drugs in,
however the performance varies across the studies where (Figure 2). Given classical machine learning methods were
generally capable of single drug predictions, we expected the cell validation performance to be better than the drug
validation. Drug validation is a harder problem given the diversity of chemical space—a model that is largely successful
on the drug validation problem can be used as a virtual screening tool for compounds. While it may appear the CCLE
samples performed better with drug validation, this is an anomaly given at most two CCLE drugs appeared in that
validation set.
Considering the case of a classification problem is often more actionable than the regression case for drug discovery
and virtual screening tasks. The specific task of the model would be to filter models molecules based on their expected
performance on CCLs which can be done at massive scale and quickly on a GPU, where inference times for these models
3
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Table 1: Metric comparison at 99-percentile of grouped by the model validation strategy and the inclusion of SNPs.
Rows do not represent a single model with those three metrics, rather a model exists with one of those metrics. A t-test
for difference between group means shows a significant difference in r2 scores p = 1.9e− 18 and 0.0005 for cell and
drug validation methods respectively.
Validation Method SNPs Included RMSE r2 score Balanced Accuracy MCC
On Cell False 0.086 0.675 0.889 0.553True 0.083 0.712 0.896 0.577
On Drug False 0.108 0.448 0.792 0.460True 0.107 0.495 0.807 0.487
Table 2: Metric comparison at 99-percentile of grouped by the model validation strategy and the scaling method used.
Rows do not represent a single model with those three metrics, rather a model exists with one of those metrics.
Validation Method RNA-seq Scaling Method RMSE r2 score Balanced Accuracy MCC
On Cell
Combat 0.084 0.708 0.893 0.568
None 0.084 0.703 0.893 0.565
Source Scaled 0.084 0.710 0.891 0.568
On Drug
Combat 0.107 0.484 0.797 0.478
None 0.110 0.470 0.795 0.474
Source Scaled 0.108 0.494 0.796 0.473
Table 3: Metric comparison at 99-percentile of grouped by the model validation strategy and the RNA-seq feature set
used. Rows do not represent a single model with those three metrics, rather a model exists with one of those metrics.
Validation Method RNA-seq Feature Set RMSE r2 score Balanced Accuracy MCC
On Cell
lincs1000 0.084 0.708 0.895 0.567
oncogenes 0.084 0.706 0.891 0.574
oncogenes & lincs1000 0.085 0.708 0.894 0.568
On Drug
lincs1000 0.108 0.478 0.796 0.482
oncogenes 0.107 0.478 0.788 0.463
oncogenes & lincs1000 0.108 0.487 0.810 0.478
Table 4: Metric comparison at 99-percentile of grouped by the model validation strategy and the drug featurization
method used. Rows do not represent a single model with those three metrics, rather a model exists with one of those
metrics.
Validation Method Drug Featurization RMSE r2 score Balanced Accuracy MCC
On Cell
Dragon7 Descriptors 0.084 0.706 0.894 0.570
Mordred Descriptors 0.084 0.708 0.889 0.568
Mordred and Dragon7 Descriptors 0.084 0.709 0.896 0.567
On Drug
Dragon7 Descriptors 0.108 0.478 0.793 0.466
Mordred Descriptors 0.107 0.473 0.811 0.481
Mordred and Dragon7 Descriptors 0.107 0.491 0.793 0.471
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well outperform standard virtual docking libraries (approx. 5000 samples per second, less if featurizing molecule
on the fly). While other techniques such as virtual docking and simulation experiments can perform similar tasks by
rank-ordering large virtual libraries, we propose the screening results from these models’ predictions can be another
measure designers of CCL panels and initial drug datasets can employ. The use of these models in the creation of new
CCL panels would hopefully be able to balance the distribution of responders versus non-responders further. Given the
models are regressors, a cutoff can be selected both at training time for using the balanced data sampling strategy and
used afterwards for a sensitivity detection cutoff (we used 0.5, for example). Type I error (false positives) is a more
costly error in the precision medicine task where the assignment of an incorrect drug is a wasted treatment opportunity,
while type II error (false negatives) is costly in the virtual library screening where missing a potential lead at an early
stage is a costly error. Of course, both errors should be considered for either task, but we aim to highlight the diversity
of models possible just by training a large collection of DNN models. By altering the regression cutoff to 0.3, one can
achieve > 90% balanced accuracy on the validation screening problem. We believe the cost analysis of virtual screening
models is beneficial to researchers, where the choice of model used in screening should come from the task at hand, not
necessarily the best state of the art performance. Further work can be done to introduce uncertainty quantification into
these models using techniques in [19].
While the prior classical assessment viewed the input data as the most significant point of variance, our results indicate
the parameterization of the deep learning problem itself to be the largest explanation of variance. Based on the results,
we see the transition from classical machine learning to deep learning will require a shift in focus from pure-feature
engineering to deep learning hyperparameter optimization. Although we did not test discordant feature sets (all genetic
features were super sets of each other, and the drug features techniques were both descriptor and fingerprint methods),
one would expect to see a large variance across them, though the predictive signal seems stable across all input features.
This implies better representations exist for drugs and cells, or perhaps the features we have selected are optimal and a
smaller set can be created.
While the hyperparameter decision tree ranked non-feature related aspects higher than the cell and drug featurizations,
the result from the percentile and ANOVA analysis should not be understated, attributing significant to use of SNP
data. For instance, the quantile analysis shows a greater difference in MCC on cell validation for the inclusion of SNPs
than the differences between MCC for the various model architectures; yet, the decision tree feature importance for the
cell validation ranks model architecture as a more useful predictor than the inclusion of SNP frames. We believe this
should be read a probability difference, rather than a discrepancy. The decision tree is attempting to model the entire
distribution of models we trained, so the fact that the optimizer has a big impact is only due to the fact that SGD is
more likely to not converge or converge to the optimum point without hyperparameter optimization while Adam is
likely to converge to the same point. In a sense, for researchers getting into deep learning, time spent understanding
hyperparameters of deep neural networks has a higher probability of paying off than feature engineering initially. The
quantile analysis, however, does indicate there are pay-offs to exploring feature sets, only if one is willing to pay the
computational cost of hyperparameter sweeps or optimization.
The results from this study indicate the choice of handling batch effect, general architecture, drug descriptors and
modalities, and even the genetic features provided do not seem to impact the performance of the best models. The
case of model architecture, dropout, and optimizers this result is not unexpected, as in general optimizers and dropout
strategies should have minimal effect on the overall model capacity. Given the various model architectures were
designed to have similar number of parameters, it seemed they were not differentiable in the case of general well
performance. Batch effect handling, for example, employs a standard neural network to reduce the batch effect in the
case of the combat scores; though this would be possible to occur within the first few layers of the network. To check,
we present the by study scores of the models in the validation set split by the batch effect standardization procedure
(Table 5) which again do not seem to indicate a noticeable effect. Other aspects such as dropout and optimizer do
not have a global effect on models as we trained many models, however there are smaller effects such as the Adam
optimizer generally performing better than SGD but this may be due to the lack of global parameter optimization,
adjusting factors such as batch size and learning rate as it is well studied that SGD requires careful selection of learning
schedule [20].
As a minor point, the choice of RNA-seq genes to use in the model was not an important consideration for model
variance. There is that no superset of LINCS1000 gene set clearly outperformed any other set. This is, however,
by design of the LINCS1000 gene set, as the selection of genetic features was created to recover most information
contained in the transcriptome [21]. Given the ability of the network to learn at such a high drop out rate, the learned
weights should have optimal sparse networks. We have shown that an optimal random subset of RNA-seq sizes is
desirable.
The SNPs improved performance all around, when looking at aggregated test statistics. The results suggest that SNPs
improved regression metric performance as well as classification metric performance, regardless of the validation
5
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strategy. It is observed that the NCI-60 cell line show over 100x mutation rates over other sources used. In order to
examine if this artifact affected the results, we again break down the performance by cross study. We see that breakdown
by study in the analysis further illustrates complexities around this type of study. The results in figure 3 indicate however
the inclusions of SNPs do not increase the performance across every study when aggregated from validation data. The
cross-study results indicate that the larger mutation profile of the NCI-60 is not skewing the result indicating SNPs
boost model performance on the cell validation split.
Both MOrderd and Dragon7 are fingerprint and descriptor based methods, with a great overlap between the two in
terms of chemiformatics information found. An interesting component is the discrepancy between the cell and drug
validation measures. When broken down by cross study, GDSC predictive performance is hurt severely when validating
on drugs, and general predictions on unseen drugs is less powerful than unseen cells. We believe this is an indication
that the models are not learning a useful representation of drugs, and further analysis of different drug modalities should
be undertaken, such as images and fingerprints in [5].
4 Conclusion
We performed a large-scale sweep over feature types and training strategies for drug response prediction models. In
doing so, we present a technique of training and testing across various cancer cell line screens. Despite the number of
models trained and evaluated, we only comment on cancer drug response models using RNAseq, SNPs, and chemical
descriptor methods. At this scale, we argue there is enough statistical (and observed) variance for researchers creating
models without the ability to perform large-scale hyperparameter optimization and architecture sweeps to take into
consideration. Of course, these results may disagree with the finding of others as one-off model optimizations will create
different results, as we base our results on 99th percentile rather than one-off model scores. Further hyperparameter
optimization should take place from this starting point. We found the inclusion of SNPs to be a significant factor for
model performance. Contrary to previous studies, we do not find features to be the largest explanation for variance
across models. We believe further work must done both in terms of architecture searches, data standardization, and
evaluation across multiple data sources.
Method
4.1 Data
In this work, we curated a collection of cancer cell line screens from four different data sources. We use the Genomics
of Drug Sensitivity (GDSC) [22], NCI-60 Human Tumor Cell Lines Screen (NCI-60) [23], the Cancer Cell Line
Encyclopedia (CCLE) [24], Cancer Therapeutics Response Portal (CTRP) [25], and the Genentech Cell Line Screening
Initiative (gSCI) [26]. Each dataset consists of a panel of cancer cell lines tested of drugs. The datasets span size
and specificity, as the NCI-60 contains the widest set of drugs, and the smallest set of cells. The datasets individually
overlap both on some cells and drugs.
Cancer types across the datasets were not reported uniformly and contained some missing data. Using an autoencoder
on RNA-seq data from the Genomic Data Commons [27], we were able to generate type-like labels for all RNA-seq
data in our uniform dataset. Due to the imbalanced representation of various cancer types, the data was limited to the 21
most prevalent cancer types represented in the combined data frames. We applied a standard cancer type clustering
technique to determine this source similarity metric (figure 4.1) [?].
4.2 Data Preprocessing
RNA-seq profiles are not provided in standard format by CTRP, gSCI, and GDSC; however, there is a mapping from
cells in CCLE and NCI-60 to obtain RNA-seq profiles. After mapping and aligning to the set of drugs from each data
frame, the cell response metric was standardized. The NCI-60 reports a dose-response metric based on cell growth after
drug application.
4.2.1 Cell Profile Processing
The gene expression datasets for cancer cell lines, generated using RNA-seq and mutation data, were collected from the
following sources: NCI-60, CCLE, and GDSC. The CTRP and gCSI drug response datasets were generated using the
cell lines from CCLE dataset. Hence, for those, we used the gene expression and mutation data from the matching
cell lines in the CCLE dataset. We refer to two featurization for cells, the RNA-seq for the expression data and single
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Table 5: Breakdown of data standardization techniques across the different studies in the validation data.
Balanced Accuracy r2 Score
validation scaling All CCLE GDSC NCI-60 All CCLE GDSC NCI-60
On Cell
Combat 0.893 0.914 0.912 0.902 0.708 0.729 0.619 0.749
None 0.893 0.918 0.906 0.904 0.703 0.73 0.617 0.743
Source Scaled 0.891 0.91 0.904 0.899 0.71 0.727 0.617 0.747
On Drug
Combat 0.797 0.945 0.799 0.854 0.484 0.762 0.378 0.607
None 0.795 0.944 0.794 0.854 0.47 0.761 0.388 0.598
Source Scaled 0.796 0.946 0.808 0.839 0.501 0.748 0.397 0.602
Figure 2: Comparison of the models’ performances between validation methods over all converged trained models
broken down by sample’s originating study.
Table 6: Individual metrics for cell split validation for two of most useful models. The regression model is a differential
dropout model with an initial dropout rate of 0.45, trained with the top 21 cancer type samples using loss weighting on
the samples. Cells were featurized with SNPs and RNA-seq from the LINCS1000 subset, and chemicals were featurized
by Dragon7 descriptors. The classification model is trained only on the top 6 cancer types and is the standard MLP
model with a dropout rate of 0.2. Cells were featurized with SNPs and RNA-seq from the LINCS1000 subset, and
chemicals were featurized by MOrdred descriptors. Both models used the Adam optimizer.
Best Regression Model Best Classification Model
r2 score RMSE Balanced Accuracy MCC r2 score RMSE Balanced Accuracy MCC
All 0.73 0.078 0.69 0.47 0.56 0.104 0.91 0.59
CCLE 0.70 0.086 0.71 0.53 0.68 0.087 0.90 0.69
GDSC 0.57 0.098 0.74 0.53 0.52 0.106 0.87 0.60
NCI60 0.76 0.075 0.68 0.45 0.56 0.103 0.92 0.58
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nucleotide polymorphisms (SNPs) for the mutation data. The SNP data was prepared as counts rather than binary
indictor of presence or absence.
The gene expression values were represented as fragments per kilobase of transcript per million (FPKM) values. To
create varying gene lists, three datasets were created. The original contains a standard set of genes by an inner join of
all the data sets (19,000 features), onco-gene set, and a LINCS1000 set. The LINCS1000 set was derived from the
gene in The Library of Integrated Network-Based Cellular Signatures (LINCS) 1000 gene set [28]. The onco-gene set
was created from a list of 2054 genes derived from the following three sources: i) 976 “landmark” human genes from
high-throughput gene expression assay used in The Library of Integrated Network-Based Cellular Signatures (LINCS)
1000 study, ii) 470 high-confidence cancer genes identified in GDSC1000 study [29], and iii) 1020 genes considered to
be cancer genes by OncoKB [30].
The genes were filtered based on the genes int he respective dataset list and the FPKM values were transformed into log
TPM values by
log
(
FPKM · 106/Sum of all FPKM values
)
,
and batch effect procresssed according to a few different methods.
When batch effects are in the data frame, the biological signal is not as strong as the effect coming from the various
batches (figure 5. This effects the downstream analysis such as differential expression and predictive modeling resulting
in bias and unpredictable behavior. In order to manage batch effects between the different RNA-seq profiling, we tested
three approaches: whole frame scaling, source scaling, and combat scores. Whole frame scaling, or applying no batch
effect handling method, merges the combined RNA-seq expression values and scaling each feature to unit norm. Source
scaling scales each feature to unit norm by the source rather than the combined data frame. Combat scaling come from
combat algorithm from Johnson [31].
4.3 Target Processing
Ideally, the target metric chosen correlates to growth inhibition used in the NCI-60 dataset for drug response measure
given the NCI-60 is the largest data source used. The growth response data for NCI-60 cell lines is prepared by
applying the compound at five different dosages to the tumor [32]. By staining the cancer cells and measuring the
absorbency with automated plate reader, they obtained the absorbency at time-zero, Tz , the control absorbency, C, and
the absorbency after the application of the drug, Ti. Growth response used in the datasets is computed as Percentage
Growth Inhibition (PGI) by
PGI =
{
100Ti−TzC−Tz Ti ≥ Tz
100Ti−TzTz Ti < Tz
. (1)
The PGI value is the target prediction value of most learning problems related to the NCI-60 dataset.
From the PGI values across the different dosages, three values are computed related to the compound and cell. First,
Growth inhibition of 50% (GI50) is calculated from setting the PGI to 50% and solving for Ti in Equation 1. The Total
Growth Inhibition (TGI) is calculated by finding the concentration of the drug where Ti = Tz . Lastly the 50% lethal
concentration (LC50) is the concentration of drug resulting in a 50% reduction in the measured protein at the end of the
drug treatment as compared to that at the beginning, which is the Ti dosage so (Ti− Tz)/Tz = −0.5.
However, this metric requires each sample is associated with a cell, drug, and a dosage. In order to remove the
dependency on dosage as the interest in cell lines is skewed toward drug screening and further downstream precision
medicine where dosage is not a preliminary question, we formulate a dose-independent drug response metric for the
datasets provided by some data sources such as CCLE.
For each dataset, we fit the dose dependent response to a hill curve with E∞, EC50, and hill sloop binding cooperatively
(HS) (table 4.3). From the fit curve, we computed AUC - area under growth curve for a fixed dose range between 4 and
10 −log10(M), IC50 - drug dose to have 50% growth, EC50se - standard error of the estimated EC50, R2fit - R2 score
between the unclipped, real growths and fitted growth values, AUC1 - area under growth curve for the measured dose
range in a study, AAC1 - area above growth curve for the measured dose range in a study, and DDS1 - drug sensitivity
score [33].
While all the metrics are highly correlated, in this paper, we study AUC for a fixed dose range across all studies from 4
to 10 − log10(M). A value of 1 for AUC indicates a cell does not respond at dosages while a value of 0 indicates a cell
responds completely at all dosages. Given most cell lines do not respond to a particular drug, the predictive target AUC
is highly skewed (Figure 1).
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4.4 Molecular Representations
The representation of molecules plays a crucial role in response prediction for it directly indicates what kind and how
much information will be given into the deep learning models during training and inference.
We can divide the representations into engineered (knowledge-based) or non-engineered ones based on whether the
featurization process involves the domain knowledge on molecular chemistry; alternatively, from the learning and
data presentation point of view, the molecular representations can be either euclidean (vectors, tensors, voxels, etc.)or
geometric (meshes, graphs, point clouds, etc.) ones.
The most basic but yet still effective representation of molecules is SMILES string. Introduced in [34] in the late 1980s,
SMILES (simplified molecular-input line-entry system) converts molecules into unique and human-understandable
ASCII strings based on a given set of rules, which can be then processed with the methods and models in natural
language processing. In our experiment, we used the canonical SMILES string, encoded them based on characters, then
fed the vectors into deep learning models. Successful results has been demonstrated [35, 36, 37] with this approach
despite the fact that this vector representation requires minimal domain knowledge.
Molecular fingerprint is a widely used method of encoding molecules based on the presence or absence of particular
substructures. There are different ways to implement such substructure encoding, some of them are non-exhaustive
such as MACCS, which only has 166 structural key, while the others are exhaustive but differs in searching patterns
(circular-, path-, or tree-based searching) and substructure specifications (such as the number of atoms in substructure).
In our experiment, we used ECFP[38], one of the most commonly used fingerprint, with different substructure size and
vector dimensions to search for the most effective ECFP features for drug response.
Molecular descriptor is a broad definition, which usually requires more domain knowledge and feature-engineering
to generate. Generally speaking, any numeric representation that can "describe" the molecules in a certain way, is
a descriptor. For the sake of better performance, a good set of descriptors often covers a wide range of molecular
properties, some of which are rather complex and demands understanding of chemistry at a very deep level to design. In
our experiment, we have tried Mordred [39] and Dragon descriptors, both of which are highly popular and widely used
in other works. In this work, we limit the exploration to molecular descriptors from MOrdered and Dragon7 code bases.
4.5 DNN Models
Unlike classical algorithms studied in previous sweeps over this problem, deep neural networks are highly parameterized
over architecture and training strategy [40]. A study of greater scale could be done just exploring the question of
architecture and training strategy for a single set of features and data. Arbitrarily, we selected three model architectures
based on experience from training models on the data, with the hope the three models are different enough to capture
any interesting variance between them.
We present three model architectures, a deep model, a model with a differential dropout scheme (inspired by the
observations from [41]), and a model with a sigmoid channel gated attention mechanism. The standard deep model is a
simple ReLU based multi-layer perceptron (MLP). The differential dropout model is the same model except the dropout
rates decrease to zero toward the output layer. The multiplicative channel gating is a two tower MLP, one for the genetic
features of the cell and one for the drug features. The towers are combined using a multiplicative channel gate.
4.5.1 Multiplicative Channel Gating
Attention mechanisms are used successfully in natural language processing (NLP) applications. Attention layers in
NLP take as input a set of keys, values, and queries and attend to certain parts of the sequence to highlight important
parts of the prediction [42]. Image attention expands the use case to images. Image attention has been used for image
captioning where the model “attends” to a region in the image to predict word used to caption that part of the image
[43]. We consider a self-attention mechanism between linear layers of a network, where an activation function (sigmoid,
tanh, softmax, etc.) is applied to one channel and multiplied onto another, effectively attending to certain values of the
activation. We employ a variety of generic activation functions such as sigmoid, tanh, or softmax. Unlike a standard
self-attention implementation such as the one used in Monica et. al [4], we do not enforce the use of softmax which can
dimension the value of the gradients for non-sequence data. By using a sigmoid or tanh function, each channel is gated
with the possibility of decreasing the value, though there is no restriction on how much information passes through the
layer, unlike a softmax function.
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4.5.2 Model Training
Three training methods were used across all models. Training was performed using Pytorch [44]. All models were
trained on Summit, where each model used a single NVIDIA Volta V100. The models were dispatched for training and
scoring using the Cancer Distributed Learning Environment (CANDLE) Supervisor [45]. Two optimizers, stochastic
gradient descent (SGD) and Adam optimizer were tested with the learning rate initially set to 8e-4 for both[46]. The
learning rate was reduced by a quarter when the validation loss did not decrease for over 20 epochs. The batch size
was not varied and set to 512. Each model was set to train for 400 epochs, and stop early if validation loss stopped
decreasing after 10 epochs. We trained using Huber loss (Smooth L1 loss) with δ = 1 [47].
Besides the standard vanilla training procedure, two other training variations were used. Due to the high imbalance
of positive leads (AUC ≤ 0.5), an imbalanced data sampling strategy was used for each batch or a weighted loss
function [48, 49]. Imbalanced data sampling fills each batch with a balanced number of responders and non-responders.
The drawback of this method is the model sees some data more than others which may lead to over-fitting on the
smaller class. Loss weighting is generally used for classification where different weights are applied to different target
predictions. As the models in this study are trained for a regression task, loss weighting for this context involves
multiplying the loss of each batch by 1− y, the target, in order to produce stronger gradients for non-responders and
weaker gradients for responders—the idea coming from the the responders, having few examples, not being able to
influence the gradient enough to push the model towards learning the smaller class. Neither strategy was tested in
conjunction with the other.
4.5.3 Model Training
Three training methods were used across all models. Training was performed using Pytorch [44]. All models were
trained on Summit, where each model used a single NVIDIA Volta V100. The models were dispatched for training and
scoring using the Cancer Distributed Learning Environment (CANDLE) Supervisor [45]. Two optimizers, stochastic
gradient descent (SGD) and Adam optimizer were tested with the learning rate initially set to 8e-4 for both[46]. The
learning rate was reduced by a quarter when the validation loss did not decrease for over 20 epochs. The batch size
was not varied and set to 512. Each model was set to train for 400 epochs, and stop early if validation loss stopped
decreasing after 10 epochs. We trained using Huber loss (Smooth L1 loss) with δ = 1 [47].
Besides the standard vanilla training procedure, two other training variations were used. Due to the high imbalance
of positive leads (AUC ≤ 0.5), an imbalanced data sampling strategy was used for each batch or a weighted loss
function [48, 49]. Imbalanced data sampling fills each batch with a balanced number of responders and non-responders.
The drawback of this method is the model sees some data more than others which may lead to over-fitting on the
smaller class. Loss weighting is generally used for classification where different weights are applied to different target
predictions. As the models in this study are trained for a regression task, loss weighting for this context involves
multiplying the loss of each batch by 1 − y, the target, in order to produce stronger gradients for non-responders
and weaker gradients for responders—the idea coming from the responders, having few examples, not being able to
influence the gradient enough to push the model towards learning the smaller class. Neither strategy was tested in
conjunction with the other.
4.6 Model Evaluation
Prior works have utilized strict and non-strict partitioning for both cell lines and drugs in the training and testing set.
Manica et al. marks the distinction between a strict and lenient split by cell and drug identity in the training set [4].
Chang et al. used a leniant (random on both cells and drugs) split for the validation data [7]. Given our dose-independent
prediction target, a specific cell and specific drug constitutes a single training example only in terms of model training
and testing.
Outside of pure model performance testing, there are two use cases we targeted: drug screening and precision medicine
screening. For drug screening, panels are often performed against the set collection of cell lines to determine if a
drug should move on to PDX models for further testing. In this case, we partition the training and test set by unique
molecules, and use a 3-fold cross validation where each fold consist of entirely different molecules. For precision
medicine, there is a list of approved drugs or known agents and the medical question is regarding which treatment to
offer to a cell. In this case, the 3-fold cross validation is done over the unique cell lines, where each fold consists of
unique cells not in any other fold. For the sake of testing more models and feature combinations, we did not perform a
completely strict model evaluation of unseen drugs and cells as the use case is outside the scope of this research.
While this problem is posed as a regression problem as the AUC values are continuous on 0 < AUC ≤ 1, viewing the
problem as classification links it directly to application of the model. Due to the extreme skew of the training/testing
distributions, r2 and root mean squared error (RMSE) may not represent whether or not the model performs well
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in the region of interest (the model may minimize residuals over a large mass of the data, ignoring the residuals
separating interesting response from no response). By artificially selecting a cutoff, 0.5, we can determine for the case
of drug screening or precision medicine whether or not the model is learning to distinguish a responder cell/drug or a
non-responder. The balance between type I and type II error is a calculation that is use-case specific and the selection of
the feature set and model from our sweep will require consideration of this trade-off. We further justify this unusual
approach to classification by the result from Jang et. al indicating discretized target variables created less performant
models from [12]
4.7 Analysis of Results
In order to test thoroughly the various proposed feature and training combinations, we tested the full combination space.
Given 198 feature sets entailing various scaling, cell profile types, and drug representations, we ran each feature set on
each model, with three different training strategies, top six and top 21 datasets, and three cross validation folds. In total,
we ran 35,320 models on Summit. We gathered the results, and concatenates the predictions on each training fold from
the model to estimate average statistics for the model.
At this scale of models, some models (15%) did not converge or provide reasonable results. Incorporating those failures
into the overall performance of a model would not encapsulate the possible performance given hyper-parameter tuning
and detailed work with a given configuration. We present models ranked by balanced accuracy and MCC to illustrate
classification performance with post-processing binning and r2 scores to illustrate the predictive power of the regression
view of the problem.
After gathering data, we removed models we believed to have not converged or over fit based on having one of the
following criteria: TPR or FPR of 1.0, negative or zero r2 score, or a loss outside the 85th quantile. This removed 2045
models from the data for analysis.
In the results section, we highlight comparisons between the drug validation models and the cell validation models. The
drug validations did not perform nearly as well as the cell validation models. We believe drug validation is a harder test
on the model as the test is based on drug discovery rather than preclinical screening for a fixed set of drugs. For metrics
such as Mathew correlation coefficient (MCC) and r2 score we report 99th percentile, and for root mean squared error
we report (0.01) percentile. We report multiple metrics as different purposes may arise for these models. We chose to
report at 99th percentile versus best models found, as it is unclear with limited resources a researcher could reproduce
the best model, and we aim to discuss approaches to the problem that can be taken out of the box and be performant.
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Figure 3: Cross study analysis of SNPs, 98th percentile and max for each score.
Figure 4: Counts of cells based on type from each dataset used in the training data. Each data source contains other
types not included, but we limit ourselves to the top 21 and top six cancer types. The types were determined based on
clustering of RNA-seq using the autoencoder clustering method. While the method is not the same as a somatic tissue
type or diagnosis, the type provides an indication of the diversity between data sources when attempting to balance data
across classes.
Source r2 fit E∞ HS
CCLE 0.71± 1.35 0.31± 0.35 1.93± 1.50
CTRP 0.70± 0.36 0.33± 0.38 2.01± 1.53
GDSC 0.63± 0.40 0.40± 0.39 1.88± 1.53
NCI-60 0.80± 43.16 0.36± 0.36 1.93± 1.47
gCSI 0.82± 0.31 0.34± 0.33 1.90± 1.28
Table 7: Dose independent fitting results. E∞ and HS are parameters from the fit, and r2 is from the result of the hill
curve fit on a per-drug , per-cell basis. The NCI-60’s large standard deviation comes from a few extreme outliers that
were removed.
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Figure 5: First two components from PCA on CCLE, GDC, and NCI-60 cell lines from our combined data frame.
Without standardization, some batch effects are clear between NCI-60 and CCLE cell lines. The two methods tested
seem to eliminate an obvious skew towards various batches.
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